C4 Therapeutics, Inc. (CCCC) Return on equity 2021–2025
C4 Therapeutics, Inc. (CCCC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-40.9%FY2025 · since FY2021: -21.5% → -40.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -40.9% | +7.8 pp |
| FY2024 | -48.8% | +5.1 pp |
| FY2023 | -53.8% | -9.5 pp |
| FY2022 | -44.3% | -22.8 pp |
| FY2021 | -21.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CCCC financial trends
CCCC RevenueCCCC Net incomeCCCC Net marginCCCC Gross profitCCCC Gross marginCCCC Operating incomeCCCC Operating marginCCCC Operating cash flowCCCC Free cash flowCCCC Capital expendituresCCCC Stock buybacksCCCC Dividends paidCCCC Total assetsCCCC Total liabilitiesCCCC Shareholders’ equityCCCC overview →